RAF1 and breast carcinoma: Notably, total and nuclear β-catenin levels were not reduced by ERK inhibition in HCC cells (Supplementary Figure S1), an observation which contrasts with a previous study showing that the RAF1-p-ERK-β-catenin pathway is required for expansion of breast cancer-initiating cells and enhanced cancer malignancy [19].